JP2016525516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016525516A5 JP2016525516A5 JP2016526515A JP2016526515A JP2016525516A5 JP 2016525516 A5 JP2016525516 A5 JP 2016525516A5 JP 2016526515 A JP2016526515 A JP 2016526515A JP 2016526515 A JP2016526515 A JP 2016526515A JP 2016525516 A5 JP2016525516 A5 JP 2016525516A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mutation
- cytokine
- mutated
- leptin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000695 Cytokines Proteins 0.000 claims 10
- 102000004127 Cytokines Human genes 0.000 claims 10
- 230000035772 mutation Effects 0.000 claims 8
- 102000016267 Leptin Human genes 0.000 claims 4
- 108010092277 Leptin Proteins 0.000 claims 4
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 4
- 229940039781 leptin Drugs 0.000 claims 4
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims 3
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims 3
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 claims 2
- 102100035304 Lymphotactin Human genes 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 claims 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 102200154281 rs267606652 Human genes 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306034.3 | 2013-07-18 | ||
| EP13306034 | 2013-07-18 | ||
| PCT/EP2014/064227 WO2015007536A2 (en) | 2013-07-18 | 2014-07-03 | Fusokines involving cytokines with strongly reduced receptor binding affinities |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019154901A Division JP6853317B2 (ja) | 2013-07-18 | 2019-08-27 | 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016525516A JP2016525516A (ja) | 2016-08-25 |
| JP2016525516A5 true JP2016525516A5 (enExample) | 2017-08-10 |
| JP6580037B2 JP6580037B2 (ja) | 2019-09-25 |
Family
ID=48906191
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526515A Active JP6580037B2 (ja) | 2013-07-18 | 2014-07-03 | 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン |
| JP2019154901A Active JP6853317B2 (ja) | 2013-07-18 | 2019-08-27 | 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019154901A Active JP6853317B2 (ja) | 2013-07-18 | 2019-08-27 | 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10640542B2 (enExample) |
| EP (2) | EP3022305B1 (enExample) |
| JP (2) | JP6580037B2 (enExample) |
| KR (1) | KR102322510B1 (enExample) |
| CN (2) | CN105705641B (enExample) |
| AU (2) | AU2014292371B2 (enExample) |
| BR (1) | BR112016001036B1 (enExample) |
| CA (1) | CA2917937C (enExample) |
| DK (1) | DK3299466T3 (enExample) |
| ES (2) | ES2657060T3 (enExample) |
| IL (1) | IL243451B (enExample) |
| MX (1) | MX375441B (enExample) |
| SG (2) | SG11201600163VA (enExample) |
| WO (1) | WO2015007536A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017077382A1 (en) | 2015-11-06 | 2017-05-11 | Orionis Biosciences Nv | Bi-functional chimeric proteins and uses thereof |
| EP3411407B1 (en) | 2016-02-05 | 2024-04-03 | Orionis Biosciences BV | Bispecific signaling agents and uses thereof |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| US11248057B2 (en) | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
| US11753463B2 (en) | 2016-05-13 | 2023-09-12 | Orionis Biosciences BV | Therapeutic targeting of non-cellular structures |
| WO2017194783A1 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Targeted mutant interferon-beta and uses thereof |
| EP3529264B1 (en) | 2016-10-24 | 2022-03-09 | Orionis Biosciences BV | Targeted mutant interferon-gamma and uses thereof |
| MX2019009255A (es) | 2017-02-06 | 2019-11-05 | Orionis Biosciences Nv | Proteínas quiméricas dirigidas y sus usos. |
| EP3576765B1 (en) | 2017-02-06 | 2025-07-16 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| CA3050601A1 (en) * | 2017-02-07 | 2018-08-16 | Vib Vzm | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| JP7423511B2 (ja) | 2017-08-09 | 2024-01-29 | オリオンズ バイオサイエンス インコーポレイテッド | Ｐｄ－１およびｐｄ－ｌ１結合物質 |
| CA3069930A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | Cd8 binding agents |
| KR102659140B1 (ko) | 2017-08-09 | 2024-04-19 | 오리오니스 바이오사이언시스 인코포레이티드 | Clec9a 결합제 및 그의 용도 |
| AU2018359420A1 (en) | 2017-10-31 | 2020-06-04 | Kalivir Immunotherapeutics, Inc. | Platform oncolytic vector for systemic delivery |
| US20200354424A1 (en) | 2018-01-26 | 2020-11-12 | Orionis Biosciences, Inc. | Xcr1 binding agents and uses thereof |
| KR102877915B1 (ko) | 2018-02-05 | 2025-10-29 | 오리오니스 바이오사이언시즈 인코포레이티드 | 섬유아세포 결합제 및 이의 용도 |
| EP3833391A4 (en) | 2018-08-08 | 2022-08-10 | Orionis Biosciences, Inc. | CHIMERIC PROTEINS TARGETED AT SIRP1alpha AND THEIR USES |
| EP3890773A4 (en) | 2018-11-08 | 2022-11-09 | Orionis Biosciences, Inc. | MODULATION OF DENDRITIC CELL LINES |
| CA3133643A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Therapeutic interferon alpha 1 proteins |
| KR20220012227A (ko) | 2019-03-28 | 2022-02-03 | 오리오니스 바이오사이언시즈 인코포레이티드 | Clec9a-기반 키메라 단백질 복합체 |
| US20230293652A1 (en) * | 2020-07-07 | 2023-09-21 | Orionis Biosciences, Inc. | Immunostimulatory adjuvants |
| KR20230110545A (ko) | 2020-11-19 | 2023-07-24 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 종양 미세환경 재형성에 의한 종양용해 면역요법 |
| TW202305125A (zh) | 2021-04-30 | 2023-02-01 | 美商凱立凡爾免疫治療股份有限公司 | 用於經修飾mhc表現之溶瘤病毒 |
| WO2024112814A1 (en) * | 2022-11-21 | 2024-05-30 | Wisconsin Alumni Research Foundation | SYNTHETIC IL6-IL1β FUSION CYTOKINE FOR PROMOTING T CELL CYTOTOXIC FUNCTION, T CELL PROLIFERATION, AND TUMORICIDAL ACTIVITY |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE103932T1 (de) * | 1989-08-22 | 1994-04-15 | Immunex Corp | Fusionsprotein bestehend aus gm-csf und il-3. |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| ATE316982T1 (de) * | 1999-08-09 | 2006-02-15 | Lexigen Pharm Corp | Mehrere zytokin-antikörper komplexen |
| AU2002236517A1 (en) * | 2000-11-29 | 2002-06-11 | University Of Southern California | Targetet retoviral vectors for cancer immunotherapy |
| CN1168740C (zh) * | 2001-04-04 | 2004-09-29 | 上海美恩生物技术有限公司 | 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途 |
| ES2381025T3 (es) * | 2001-12-04 | 2012-05-22 | Merck Patent Gmbh | Inmunocitocinas con selectividad modulada |
| DE602004031341D1 (de) * | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| EP1598364A1 (en) * | 2004-05-21 | 2005-11-23 | AGIRx Limited | Chimerical soluble hyper IL-11 receptor and use thereof |
| CA2585549A1 (en) | 2004-11-18 | 2006-05-26 | Vib Vzw | Novel type leptin receptor antagonist |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| US7947265B2 (en) | 2006-08-02 | 2011-05-24 | Mcgill University | Fusion proteins and methods for modulation of immune response |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| JP2010531666A (ja) | 2007-06-26 | 2010-09-30 | ユニバーシティ オブ マイアミ | 抗体−エンドスタチン融合タンパク質及びそのバリアント |
| EP2853267B1 (en) | 2007-09-21 | 2016-12-07 | The Regents of the University of California | Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| WO2010036918A2 (en) | 2008-09-26 | 2010-04-01 | University Of Massachusetts | Intracellular dna receptor |
| AU2009326075B2 (en) | 2008-12-08 | 2014-06-05 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| CA2769619C (en) | 2009-08-17 | 2019-04-30 | Roche Glycart Ag | Targeted immunoconjugates |
| WO2011029870A1 (en) | 2009-09-10 | 2011-03-17 | Cytos Biotechnology Ag | Use of interleukin-1 beta mutein conjugates in the treatment of diabetes |
| CN105031618A (zh) * | 2009-11-02 | 2015-11-11 | 加利福尼亚大学董事会 | 用于细胞因子递送的穹窿体复合物 |
| KR101548567B1 (ko) * | 2009-12-23 | 2015-09-01 | 그래댈리스, 인코포레이티드 | 푸린―녹다운 및 ｇｍ―ｃｓｆ―증강된 (ｆａｎｇ) 암 백신 |
| AU2011243965A1 (en) * | 2010-04-22 | 2012-12-06 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | High affinity leptins and leptin antagonists |
| CN102372780A (zh) * | 2010-08-23 | 2012-03-14 | 上海市计划生育科学研究所 | 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用 |
| US9534056B2 (en) | 2011-06-06 | 2017-01-03 | Immungene Inc | Engineered TAA antibody-TNFSF member ligand fusion molecules |
| EA034989B1 (ru) | 2011-10-28 | 2020-04-15 | Тева Фармасьютикал Австралия Пти Лтд | Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон |
| WO2013107791A1 (en) * | 2012-01-20 | 2013-07-25 | Vib Vzw | Targeted mutant alpha-helical bundle cytokines |
| WO2013134138A1 (en) | 2012-03-03 | 2013-09-12 | Immungene, Inc. | Engineered antibody-interferon mutant fusion molecules |
| EA037749B1 (ru) * | 2014-10-29 | 2021-05-18 | Тева Фармасьютикалз Острэйлиа Пти Лтд | ВАРИАНТЫ ИНТЕРФЕРОНА 2b |
-
2014
- 2014-07-03 ES ES14734831.2T patent/ES2657060T3/es active Active
- 2014-07-03 EP EP14734831.2A patent/EP3022305B1/en active Active
- 2014-07-03 MX MX2016000611A patent/MX375441B/es active IP Right Grant
- 2014-07-03 JP JP2016526515A patent/JP6580037B2/ja active Active
- 2014-07-03 US US14/905,343 patent/US10640542B2/en active Active
- 2014-07-03 CN CN201480040538.3A patent/CN105705641B/zh active Active
- 2014-07-03 EP EP17195867.1A patent/EP3299466B1/en active Active
- 2014-07-03 BR BR112016001036-1A patent/BR112016001036B1/pt active IP Right Grant
- 2014-07-03 ES ES17195867T patent/ES2757501T3/es active Active
- 2014-07-03 WO PCT/EP2014/064227 patent/WO2015007536A2/en not_active Ceased
- 2014-07-03 SG SG11201600163VA patent/SG11201600163VA/en unknown
- 2014-07-03 CN CN201911159381.7A patent/CN110835376B/zh active Active
- 2014-07-03 AU AU2014292371A patent/AU2014292371B2/en active Active
- 2014-07-03 CA CA2917937A patent/CA2917937C/en active Active
- 2014-07-03 SG SG10201808738WA patent/SG10201808738WA/en unknown
- 2014-07-03 DK DK17195867T patent/DK3299466T3/da active
- 2014-07-03 KR KR1020167002676A patent/KR102322510B1/ko active Active
-
2016
- 2016-01-03 IL IL24345116A patent/IL243451B/en active IP Right Grant
-
2018
- 2018-06-01 AU AU2018203868A patent/AU2018203868B2/en active Active
- 2018-08-14 US US16/103,302 patent/US11358997B2/en active Active
-
2019
- 2019-08-27 JP JP2019154901A patent/JP6853317B2/ja active Active
-
2022
- 2022-04-29 US US17/733,026 patent/US12410222B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016525516A5 (enExample) | ||
| Weitzenfeld et al. | The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer | |
| JP2016529232A5 (enExample) | ||
| Koelink et al. | Targeting chemokine receptors in chronic inflammatory diseases: an extensive review | |
| Fedderke et al. | Does massive funding support of researchers work?: Evaluating the impact of the South African research chair funding initiative | |
| JP2016527221A5 (enExample) | ||
| EA201791137A1 (ru) | Новые замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств | |
| WO2016090329A3 (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
| EP3749686A4 (en) | ADHESION RECEPTOR CONSTRUCTION AND THEIR USES IN NATURAL KILLER CELL IMMUNOTHERAPY | |
| JP2017206548A5 (enExample) | ||
| MX373805B (es) | Agonistas de receptor fgf21 y usos del mismo. | |
| ZA201705167B (en) | Protein associated with disease resistance and encoding gene thereof, and use thereof in regulation of plant disease resistance | |
| PH12017502099A1 (en) | Methods for diagnosing and assessing treatment for cushing's syndrome | |
| Whistler | Patwin folk-taxonomic structures | |
| EP3875470A4 (en) | CHIMERIC ANTIGEN WITH ENHANCED MULTI-IMMUNE FUNCTION BY SPECIFIC BINDING TO A TARGET CELL, AND USE THEREOF | |
| EP3843761A4 (en) | Chimeric oncolytic herpesvirus that stimulate an antitumor immune response | |
| Coe et al. | Back in Time | |
| World Health Organization | Travel and transport risk assessment: Interim guidance for public health authorities and the transport sector | |
| Starzyńska et al. | III ogólnopolska konferencja naukowa „Zarządzanie współczesnymi przedsiębiorstwami. Współczesne problemy gospodarcze w oczach młodego pokolenia”: Third National Scientific Conference „Managing today's enterprises. Contemporary economic problems in the eyes of the young generation” | |
| 柴山史朗 | IFN-α Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity. | |
| JP2016113832A5 (enExample) | ||
| Mitra | Criminology-Crime and Correctional Administration | |
| Kellogg | Bound Manuscripts and Published Volumes-Topical File of Works, ca. 1890-1940-Diseases, diagnosis, and treatment | |
| Feng | Humanistic Value Qrientation of Marx's View of Institution and Institutional Innovation | |
| Marble | Contacting the Staff Council |